Treatment of Hypercalcemia of Malignancy With Intravenous Etidronate

A Controlled, Multicenter Study

the Hypercalcemia Study Group

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

In a prospective, randomized, double-blind, multicenter study, 202 patients with cancer from 19 medical centers were treated for hypercalcemia of malignancy with daily intravenous infusions of etidronate disodium (136 patients) or saline alone (66 patients) for 3 consecutive days. Patients also received up to 3.25 L of saline daily during the treatment period. Of 157 patients for whom data could be evaluated for efficacy, 63% (72/114) of etidronate-treated and 33% (14/43) of saline-treated patients had a normalization of total serum calcium levels. When serum calcium levels were adjusted for albumin (147 assessable patients), 24% of the etidronate- and 7% of the saline-treated patients responded to treatment. No serious side effects or treatmentrelated deaths occurred. When accompanied by adequate hydration and diuresis, intravenous etidronate was safe and more effective than hydration and diuresis alone in controlling hypercalcemia of malignancy.

Original languageEnglish
Pages (from-to)471-476
Number of pages6
JournalArchives of Internal Medicine
Volume151
Issue number3
DOIs
StatePublished - 1991

Fingerprint

Etidronic Acid
Hypercalcemia
Multicenter Studies
Neoplasms
Diuresis
Therapeutics
Calcium
Serum
Double-Blind Method
Intravenous Infusions
Albumins

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Cite this

Treatment of Hypercalcemia of Malignancy With Intravenous Etidronate : A Controlled, Multicenter Study. / the Hypercalcemia Study Group.

In: Archives of Internal Medicine, Vol. 151, No. 3, 1991, p. 471-476.

Research output: Contribution to journalArticle

@article{686439199e2e44b89e8eab9fde375187,
title = "Treatment of Hypercalcemia of Malignancy With Intravenous Etidronate: A Controlled, Multicenter Study",
abstract = "In a prospective, randomized, double-blind, multicenter study, 202 patients with cancer from 19 medical centers were treated for hypercalcemia of malignancy with daily intravenous infusions of etidronate disodium (136 patients) or saline alone (66 patients) for 3 consecutive days. Patients also received up to 3.25 L of saline daily during the treatment period. Of 157 patients for whom data could be evaluated for efficacy, 63{\%} (72/114) of etidronate-treated and 33{\%} (14/43) of saline-treated patients had a normalization of total serum calcium levels. When serum calcium levels were adjusted for albumin (147 assessable patients), 24{\%} of the etidronate- and 7{\%} of the saline-treated patients responded to treatment. No serious side effects or treatmentrelated deaths occurred. When accompanied by adequate hydration and diuresis, intravenous etidronate was safe and more effective than hydration and diuresis alone in controlling hypercalcemia of malignancy.",
author = "{the Hypercalcemia Study Group} and Singer, {Frederick R.} and Ritch, {Paul S.} and Lad, {Thomas E.} and Ringenberg, {Q. Scott} and Schiller, {Joan H.} and Recker, {Robert R.} and Elisabeth Ryzen",
year = "1991",
doi = "10.1001/archinte.1991.00400030039007",
language = "English",
volume = "151",
pages = "471--476",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "3",

}

TY - JOUR

T1 - Treatment of Hypercalcemia of Malignancy With Intravenous Etidronate

T2 - A Controlled, Multicenter Study

AU - the Hypercalcemia Study Group

AU - Singer, Frederick R.

AU - Ritch, Paul S.

AU - Lad, Thomas E.

AU - Ringenberg, Q. Scott

AU - Schiller, Joan H.

AU - Recker, Robert R.

AU - Ryzen, Elisabeth

PY - 1991

Y1 - 1991

N2 - In a prospective, randomized, double-blind, multicenter study, 202 patients with cancer from 19 medical centers were treated for hypercalcemia of malignancy with daily intravenous infusions of etidronate disodium (136 patients) or saline alone (66 patients) for 3 consecutive days. Patients also received up to 3.25 L of saline daily during the treatment period. Of 157 patients for whom data could be evaluated for efficacy, 63% (72/114) of etidronate-treated and 33% (14/43) of saline-treated patients had a normalization of total serum calcium levels. When serum calcium levels were adjusted for albumin (147 assessable patients), 24% of the etidronate- and 7% of the saline-treated patients responded to treatment. No serious side effects or treatmentrelated deaths occurred. When accompanied by adequate hydration and diuresis, intravenous etidronate was safe and more effective than hydration and diuresis alone in controlling hypercalcemia of malignancy.

AB - In a prospective, randomized, double-blind, multicenter study, 202 patients with cancer from 19 medical centers were treated for hypercalcemia of malignancy with daily intravenous infusions of etidronate disodium (136 patients) or saline alone (66 patients) for 3 consecutive days. Patients also received up to 3.25 L of saline daily during the treatment period. Of 157 patients for whom data could be evaluated for efficacy, 63% (72/114) of etidronate-treated and 33% (14/43) of saline-treated patients had a normalization of total serum calcium levels. When serum calcium levels were adjusted for albumin (147 assessable patients), 24% of the etidronate- and 7% of the saline-treated patients responded to treatment. No serious side effects or treatmentrelated deaths occurred. When accompanied by adequate hydration and diuresis, intravenous etidronate was safe and more effective than hydration and diuresis alone in controlling hypercalcemia of malignancy.

UR - http://www.scopus.com/inward/record.url?scp=0025974180&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025974180&partnerID=8YFLogxK

U2 - 10.1001/archinte.1991.00400030039007

DO - 10.1001/archinte.1991.00400030039007

M3 - Article

VL - 151

SP - 471

EP - 476

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 3

ER -